According to a new market report published by Persistence Market Research “Global Market Study on Human Insulin: Asia Pacific to Witness fastest Growth by 2020,” the global human insulin market was valued at USD 24,332.6 million in 2014 and was expected to grow at a CAGR of 12.4% from 2014 to 2020, to reach an estimated value of USD 49,197.3 million in 2020.
- Novo Nordisk A/S.
- Eli Lilly and Company.
- Tonghua Dongbao Pharmaceutical Co., Ltd.
- Adocia, Merck & Co., Inc.
- Pfizer, Inc.
- Bristol-Myers Squibb Company.
- GlaxoSmithKline Plc.
- Oramed Pharmaceuticals, Inc.
Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/3308
Globally, the human insulin market is witnessing significant growth due to increasing prevalence of diabetes and increasing awareness among people about diabetes care. In addition, technological advancements in insulin delivery devices and increasing prevalence of lifestyle related disorders such as obesity are also driving the growth of the market. However, uneven pricing and limited access to human insulin in emerging countries such as Brazil, India, and China are inhibiting the growth of the human insulin market. In addition, strict regulatory requirements for drug approval are also restraining the growth of the market. The global human insulin market was anticipated to grow from an estimated USD 24,332.6 million in 2014 to USD 49,197.3 million in 2020 at a CAGR of 12.4% during the forecast period.
In North America, increasing prevalence of diabetes with growing age and availability of advanced human insulin infusion devices are driving the use of human insulin in the market.
Get a Customized Scope to Match Your Need Ask an Expert- firstname.lastname@example.org
In addition, increasing prevalence of lifestyle associated disorders such as obesity is also boosting the growth of the human insulin market in this region. For instance, according to the Centers for Diseases Control and Prevention (CDC), a U.S.-based national public health institute, over one-third children and adolescents were obese in 2012 in the U.S.
In Europe, the human insulin market is driven by rising aging population and increasing prevalence of diabetes. In addition, in Germany the market is evolving due to rising prevalence of diabetes and increasing awareness among people about diabetes care. However, in Asia-Pacific the growth for human insulin is much higher than developed countries due to increasing prevalence of diabetes and increasing government initiatives for improving healthcare.
Access Full Report@ https://www.persistencemarketresearch.com/checkout/3308
Read More Trending “PMR Exclusive Article”-
Pulmonary Fibrosis Treatment Market–Pulmonary Fibrosis Treatment Market Segmented By Monotherapy, Combination Therapy with Idiopathic Pulmonary Fibrosis (IPF), Familial PF Indication
About Us: – Persistence Market Research
Persistence Market Research
Address – 305 Broadway, 7th FloorNew York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – email@example.com
Website – https://www.persistencemarketresearch.com
Why pay for news and opinions when you can get them for free?
Subscribe for free now!
NEWS24 hours ago
Heavy winter sweaters, coats pile up at stores as warm weather threatens holiday shopping season
INVESTING3 days ago
3 Ways to Revolutionize Retail Trading
NEWS3 days ago
Oil jumps 3% as steep US crude stocks draw adds to supply concerns
INVESTING4 days ago
Digital Assets: The New Frontier in Retail Investing